Pyridostigmine Bromide

CHEMBL812 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
261.1 g/mol
LogP
Phase
4

Pyridostigmine bromide is the bromide salt form of pyridostigmine, a reversible cholinesterase inhibitor used for the symptomatic treatment of myasthenia gravis and as a prophylactic agent against organophosphate nerve agent poisoning. See pyridostigmine for complete pharmacological details.

Молекулярная масса

261,1200 g/mol

TPSA

33,40 Ų

Терапевтические области

Механизм действия

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-]

InChI

InChI=1S/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1

Molecular Formula

C9H13BrN2O2

HBD / HBA

- / 3

Вращаемые Связи

2

Тяжёлые Атомы

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Pyridostigmine bromide is the bromide salt form of pyridostigmine, a reversible cholinesterase inhibitor used for the symptomatic treatment of myasthenia gravis and as a prophylactic agent against organophosphate nerve agent poisoning. See pyridostigmine for complete pharmacological details.

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Yes, Pyridostigmine Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL812. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 7550. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.